Y-27632 2HCl is a selective ROCK1 and ROCK2 inhibitor with a Ki of 140 nM and 300nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.
Y-27632按每小时0.55 μL通过植入泵持续处理表达Val14-RhoA的大鼠,持续11天,延迟 MM1 细胞入侵。 S1049作用于肺循环,通过抑制ROCK, 降低 缺氧诱导的血管生成,和血管重构。 产品名称:Selleck Y-27632 2HCL ROCk1抑制剂 50mg 产品货号:S1049 现货供应,欢迎咨询 欢迎您的致电 400 021 2200 150 2101 0459 Selleck...
Thus, an inhibitor of ROCK pathway (Y-27632, Selleckchem) was used and a calcium chelator (BAPTA-AM, Enzo) for the inhibition of the PKC pathway. The expression of MAPKs was analyzed by western blot. Migration after stimulation with recombinant Wnt5a protein was analyzed by the wound ...
The ROCK inhibitor Y-27632 enhances 3D colon cancer cell invasiveness. (A) Left, representative micrographs of SW620 human colon cancer cells in control condition (vehicle 0.1% DMSO, CTL) or treated for 24 h, 48 h or 72 h in presence of 30 µM TTX or 10 µM Y-27632. Scale bar,...
Selleck S1049 Y-27632 2HCI,ROCK1 抑制剂 10mM/ 2mg/ 5mg/ 10mg/50mg,产品说明: Y-27632 2HCl是一种选择性ROCK1(p160ROCK)抑制剂,无细胞试验中Ki为140 nM,比对其他激酶包括PKC,cAMP依赖性蛋白激酶,MLCK和PAK的作用强200多倍。 体外研究:Y-27632也同等有效抑制ROCK-II。Y-27632作用于PKC, cAMP依赖的蛋白...
S6390Y-27632Y-27632 is a selective ROCK1 and ROCK2 inhibitor with a Ki of 140 nM and 300nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK. Nat Commun, 2025, 16(1):1130 ...
2.8. Y-27632 is a potential specific inhibitor of Em-ROCK Although the activity, but not specificity of the drugs was tested in this study, some lines of evidence support the specificity of GSK429286A and Y-27632 to Em-ROCK. The potential off target effects of the drugs were already disc...
Using the commercially available Rho kinase inhibitor Y27632, cardiac fibroblasts were treated with the respective inhibitor prior to stimulation with TGF-β. Y27632 at concentrations of 10–50 μM showed dose dependent inhibition of the expression of MMP9. Indeed, compared to the TGF-...
Belumosudil (KD025, SLx-2119) is an orally available, and selective ROCK2 inhibitor with IC50 and Ki of 60 nM and 41 nM, respectively. Phase 2.
the ROCK-inhibitor is selected from the group consisting of GSK269962A, Fasudil, RKI-1447, and Y27632; b. the RAF-inhibitor is selected from the group consisting of PLX4720 (Vemurafenib), and GSK2118436 (Dabrafenib); c. the ERK-inhibitor is selected from the group consisting of SCH772984 ...